Bank of New York Mellon Corp - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 28 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2019$17,000
-59.5%
25,0560.0%0.00%
Q2 2019$42,000
-33.3%
25,0560.0%0.00%
Q1 2019$63,000
-3.1%
25,056
-2.8%
0.00%
Q4 2018$65,000
-50.0%
25,7830.0%0.00%
Q3 2018$130,000
+54.8%
25,783
-0.0%
0.00%
Q2 2018$84,000
-9.7%
25,784
-0.1%
0.00%
Q1 2018$93,000
+75.5%
25,809
-17.1%
0.00%
Q3 2017$53,000
-31.2%
31,144
+7.6%
0.00%
Q2 2017$77,00028,9440.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$5,582,0000.54%
Cormorant Asset Management, LP 201,000$876,0000.10%
PUTNAM INVESTMENTS LLC 575,692$2,510,0000.01%
Alyeska Investment Group, L.P. 89,722$391,0000.00%
BLACKROCK ADVISORS LLC 463,200$2,020,0000.00%
Sonora Investment Management, LLC 1,500$7,0000.00%
SECURIAN ASSET MANAGEMENT, INC 14,008$61,0000.00%
MACKENZIE FINANCIAL CORP 29,208$127,0000.00%
Tower Research Capital LLC (TRC) 336$1,0000.00%
MORGAN STANLEY 12$00.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders